Results 301 to 310 of about 59,924 (341)

Off-Patent Drug Repositioning

Journal of Chemical Information and Modeling, 2020
Drug repositioning aims to reuse "old" drugs to treat diseases outside their approved indication(s). Composition-of-matter patents and FDA exclusivities can hinder the immediate availability of some drugs to be repositioned (repurposed). Here, we analyze data from the FDA Orange Book and use current on-market patent validity and exclusivities to ...
Sorin Avram, Ramona Curpan, Liliana Halip, Alina Bora, Tudor I. Oprea   +4 more
openaire   +3 more sources

Network-based drug repositioning

Molecular BioSystems, 2013
Network-based computational biology, with the emphasis on biomolecular interactions and omics-data integration, has had success in drug development and created new directions such as drug repositioning and drug combination. Drug repositioning, i.e., revealing a drug's new roles, is increasingly attracting much attention from the pharmaceutical ...
Zikai, Wu, Yong, Wang, Luonan, Chen
openaire   +2 more sources

Drug repositioning for Alzheimer's disease

Nature Reviews Drug Discovery, 2012
Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive ...
Corbett, Anne, Pickett, James, Burns, Alistair, Corcoran, Jonathan, Dunnett, Stephen B, Edison, Paul, Hagan, Jim J, Holmes, Clive, Jones, Emma, Katona, Cornelius, Kearns, Ian, Kehoe, Patrick, Mudher, Amrit, Passmore, Anthony, Shepherd, Nicola, Walsh, Frank, Ballard, Clive, Passmore, Peter   +17 more
openaire   +4 more sources

Network‐Based Approaches for Drug Repositioning

Molecular Informatics, 2021
AbstractWith deep learning creeping up into the ranks of big data, new models based on deep learning and massive data have made great leaps forward rapidly in the field of drug repositioning. However, there is no relevant review to summarize the transformations and development process of models and their data in the field of drug repositioning.
Tao Song, Gan Wang, Mao Ding, Alfonso Rodriguez‐Paton, Xun Wang, Shudong Wang   +5 more
openaire   +2 more sources

Drug Repositioning on the Cloud

2011 IEEE Third International Conference on Cloud Computing Technology and Science, 2011
Market pressures have driven pharmaceutical companies to reassess their current drug development model and reach out to new innovative business models such as drug repositioning. Various techniques that are used in drug repositioning lend themselves to the distributed computing model. The \cloud is one such computing model that optimizes resource usage
Virvilis V., Sharma A., Koutsokeras M.
openaire   +1 more source

Drug Repositioning Through Network Pharmacology

Current Topics in Medicinal Chemistry, 2016
Low drug productivity has been a significant problem of the pharmaceutical industry for several decades even though numerous novel technologies were introduced during this period. Currently pharmacologic dogma, "single drug, single target, single disease", is at the root of the lack of drug productivity.
Hao, Ye, Jia, Wei, Kailin, Tang, Ritchie, Feuers, Huixiao, Hong   +4 more
openaire   +2 more sources

Systematic Drug Repositioning

2017
This chapter focuses on the basic elements of computational drug repositioning and overviews the various in silico, in vivo, and in vitro approaches. It describes the use of Systematic Drug Repositioning (SDR) technologies to predict hitherto unknown adverse drug reactions (ADRs), or to derive mechanistic explanations of known ADRs.
Spyros N. Deftereos, Aris Persidis, Andreas Persidis, Eftychia Lekka, Christos Andronis, Vassilis Virvillis   +5 more
openaire   +1 more source

Repositioning Drugs: A Computational Approach

Current Drug Research Reviews
Abstract: Computational drug repositioning has emerged as an efficient approach to discovering new indications for existing drugs, offering lower risk and cost compared to traditional drug discovery methods.
Bhawna Sharma, Iti Chauhan, Rohit Pandey, Raj Kumar Tiwari, Gaurav Kumar, Gaurav Pratap Singh   +5 more
openaire   +2 more sources

[Drug repositioning].

La Revue du praticien
DRUG REPOSITIONING. Developing new therapeutic agents ("de novo") for human diseases is an increasingly lengthy and costly process, aimed at ensuring patient safety and drug efficacy. An alternative approach, drug repurposing or repositioning, involves using already commercialized or advanced molecules.
Clémence, Réda, Bruno, Villoutreix, Andrée, Delahaye-Duriez   +2 more
openaire   +1 more source

Computational Drug Repositioning for Cancer Therapeutics

Current Topics in Medicinal Chemistry, 2015
Due to ever-increasing failure rates, high cost, unsatisfactory safety profile, and limited efficacy associated with anticancer drug development, the repositioning of established non-cancer drugs for new oncology indications has emerged as an increasingly attractive approach to addressing the unmet cancer-related medical need.
Mingkun, Jiao, Gang, Liu, Yu, Xue, Chunyong, Ding   +3 more
openaire   +2 more sources